HAVN Life Signs Agreement to Supply Psilocybin for Mycotopia Therapies
HAVN Life Signs Agreement to Supply Psilocybin for Mycotopia Therapies
The partnership will further industry growth for naturally derived psilocybin
這一合作伙伴關係將進一步促進天然提取裸蓋菇素的行業增長
VANCOUVER, BC / ACCESSWIRE / August 25, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, recently signed an agreement to supply naturally-derived psilocybin to Mycotopia Therapies (OTC: TPIA) for their psychedelic therapies.
温哥華，BC/ACCESSWIRE/2021年8月25日/哈文生命科學公司(CSE：HAVN)(場外粉色：HAVLF)(FSE：5NP)(“公司”或“Havn Life”)一家生物技術公司追求迷幻化合物的標準化提取，以創建支持大腦健康和增強智力能力的原料藥，該公司最近簽署了一項協議，向Mycotopia療法(場外交易代碼：TPIA)供應天然衍生的裸蓋菇素用於迷幻療法。
Headquartered in Florida, Mycotopia Therapies uses psilocybin to treat people dealing with anxiety, depression, bipolar disorders, PTSD, ADHD, autism, and addictions. Their approach is technology-focused, data-driven, and utilizes medical-based solutions as part of their therapies. They aim to help individuals heal and reclaim their life, and endeavor to guide individuals through a journey of healing. In addition to their work around psychedelic therapies, they're also exploring the different ways in which psychedelics can be ingested for treatment through inhalers, vaporizers, topical methods, tinctures, ingestible capsules, and edibles.
總部設在佛羅裏達州的Mycotopia Treatures使用裸蓋菇素治療焦慮、抑鬱、躁鬱症、創傷後應激障礙、ADHD、自閉症和成癮。他們的方法以技術為重點，以數據為驅動，並將基於醫療的解決方案作為其治療的一部分。他們的目標是幫助個人治癒和重新找回他們的生活，並努力引導個人度過一段療愈之旅。除了他們在迷幻療法方面的工作外，他們還在探索通過吸入器、霧化器、外用方法、酊劑、可食用膠囊和食物來攝取迷幻藥進行治療的不同方式。
"HAVN Life and Mycotopia Therapies are a natural fit as partners; both companies share a research-based approach to psilocybin and a deep dedication to bettering human health," says HAVN Life CEO, Tim Moore. "This new partnership advances our efforts to supply safe, quality controlled psilocybin medicine to researchers and patients around the globe. We're thrilled our partner Hypha Wellness was able to introduce us to Mycotopia Therapies and facilitate a successful agreement."
HAVN Life首席執行官蒂姆·摩爾表示：“HAVN Life和Mycotopia療法作為合作伙伴是天作之合；兩家公司都對裸蓋菇素採取了以研究為基礎的方法，並致力於改善人類健康。”這一新的合作關係推動了我們向全球的研究人員和患者供應安全、質量受控的裸蓋菇素藥物的努力。我們很高興我們的合作伙伴Hypha Wellness能夠向我們介紹黴菌療法，並促成了一項成功的協議。“
The psilocybin provided to Mycotopia Therapies will come from HAVN Labs' Jamaican facility, where it works directly with Hypha Wellness to produce regulated medical psilocybin. The partnership between HAVN Life and Hypha Wellness was finalized in March 2021 and allows HAVN to optimize and refine their distribution and efficiency.
提供給Mycotopia治療的裸蓋菇素將來自HAVN Labs的牙買加工廠，在那裏它直接與Hypha Wellness合作生產受監管的醫用裸蓋菇素。HAVN Life和Hypha Wellness之間的合作伙伴關係於2021年3月敲定，使HAVN能夠優化和完善他們的分佈和效率。
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer
我謹代表董事會
蒂姆·摩爾
首席執行官
About HAVN Life Sciences Inc.
HAVN生命科學公司簡介
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.
HAVN生命科學公司是一家生物技術公司，致力於迷幻化合物的標準化提取，用於原料藥的創建、天然保健品的開發以及支持大腦健康和增強智力能力的創新療法。
Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
通過其研究部門HAVN Labs，該公司開發了標準化的、自然衍生的迷幻化合物的端到端供應鏈，用於將定義現代醫學未來的研究。憑藉其新的天然保健品系列，HAVN Life提供全方位的高質量蘑菇和植物提取物，幫助增強免疫功能，減少炎症，支持健康的生活方式。
Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.
購買我們的產品並在Your havnlife.com上了解更多信息，並在Facebook、Twitter、Instagram和YouTube上關注我們。
About Mycotopia Therapies
關於真菌病的治療
Mycotopia Therapies Inc. provides psychedelic therapies through technology-focused, data-driven, and medical-based solutions for people dealing with anxiety, depression, bipolar disorders, PTSD, ADHD, autism, and addictions. With a primary focus of helping you heal and reclaim your life, Mycotopia Therapy endeavors to guide individuals through their journey of healing. This is accomplished by acquiring an understanding of the causes and works to mental wellness through psychedelic enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years. The company operates as a subsidiary of EHAVE, Inc. Additional information on Mycotopia Therapy can be found on the Company's website at: https://www.mycotopiatherapies.com
Mycotopia Treatment Inc.通過專注於技術、數據驅動和基於醫療的解決方案，為治療焦慮、抑鬱、雙相情感障礙、創傷後應激障礙、多動症、自閉症和成癮的人提供迷幻療法。以幫助你治癒和找回你的生活為主要重點，黴菌之鄉治療致力於引導個人完成他們的康復之旅。這是通過通過迷幻增強型心理治療獲得對心理健康的原因和工作的瞭解，並與心理健康從業者和尖端技術的專業團隊相結合來實現的。迷幻療法是一種提供治癒的整體和精神方法，多年來一直顯示出成功的治療方法。該公司作為eHave公司的子公司運營。有關黴菌療法的更多信息可在公司網站上找到，網址是：https://www.mycotopiatherapies.com。
Contact:
聯繫方式：
Investor Relations: ir@havnlife.com 604 687-7130
Media: savi@emergence-creative.com 647 896-8078
投資者關係部：IR@havnlife.com 604 687-7130
媒體：Savi@Emerging-Creative.com 647 896-8078
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.
前瞻性信息：本新聞稿包含符合適用證券法的“前瞻性信息”，這些信息與有關公司業務、產品和公司業務未來的陳述有關。儘管公司認為前瞻性信息中反映的預期是合理的，但不能保證這些預期將被證明是正確的。告誡讀者不要過度依賴前瞻性信息。這些前瞻性陳述會受到風險和不確定因素的影響，這些風險和不確定因素可能會導致實際結果、業績和發展與這些陳述中預期的大不相同，這些風險主要取決於公司的產品和計劃與本新聞稿中陳述的風險不同，以及公司可能無法按預期執行其業務計劃。除法律另有規定外，公司明確表示不承擔任何義務，也不打算更新本新聞稿中的任何前瞻性陳述或前瞻性信息。儘管公司認為前瞻性信息中反映的預期是合理的，但不能保證這些預期將被證明是正確的。本新聞稿中的陳述是自本新聞稿發佈之日起作出的。
The CSE has not reviewed, approved or disapproved the content of this press release
CSE未審查、批准或不批准本新聞稿的內容
SOURCE: Havn Life Sciences Inc.
資料來源：HAVN生命科學公司。
譯文內容由第三人軟體翻譯。